Showing results (331-340 of 483) with videos related to

Sort By:
Pageof 49
The Lancet. Haematology|March 16, 2019
High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trialColin A Hutchison, Paul Cockwell, Veronica Moroz, et al.
Radiology|June 2, 2012
Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot studyNina F Schwenzer, Christina Schraml, Mark Müller, et al.
Hemasphere|September 4, 2023
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi StudyKarthik Ramasamy, Hervé Avet-Loiseau, Cecilie Hveding Blimark, et al.
JAMA|June 27, 2023
CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase SyndromeAnn-Christin Pecher, Luca Hensen, Reinhild Klein, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|March 2, 2023
Photon-Counting Computed Tomography - Basic Principles, Potenzial Benefits, and Initial Clinical ExperienceThomas Stein, Alexander Rau, Maximilian Frederik Russe, et al.
Oncology Reports|January 21, 2011
Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCCJohannes D Schultz, Sarah Rotunno, Philipp Erben, et al.
Anticancer Research|June 11, 2013
Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitroClaudia Umbreit, Christoph Aderhold, Anne Faber, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 8, 2015
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III TrialKatja Weisel, Meletios Dimopoulos, Kevin W Song, et al.
Annals of Hematology|June 16, 2026
Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysisMarie Harzer, Nils Gross-Fengels, Fede Melzer, et al.
Blood Advances|November 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myelomaJacob Stroh, Anja Seckinger, Michael Heider, et al.
Pageof 49